Standard Glass Lining IPO

Incorporated in September 2012, Standard Glass Lining Technology Limited is a manufacturer of engineering equipment for the pharmaceutical and chemical sectors in India. The company has the capability to manage the entire production process in-house. The company provides turnkey solutions, including design, engineering, manufacturing, assembly, installation, and standard operating procedures for pharmaceutical and chemical manufacturers. The company's product product portfolio includes Reaction Systems; Storage, Separation and Drying Systems; and Plant, Engineering and Services The company manufactures specialized engineering equipment using glass-lined materials, stainless steel, and nickel alloy. The company's customer includes Apitoria Pharma Private Limited, Aurobindo Pharma Limited, CCL Food and Beverages Private Limited, Cohance Lifesciences Limited, Cadila Pharmaceutical Limited, Deccan Fine Chemicals (India) Private Limited, Dasami Lab Private Limited, Laurus Labs Limited, Granules India Limited, Macleods Pharmaceuticals Limited, MSN Laboratories Private Limited, Natco Pharma Limited, Honour Lab Limited, Hetero Drugs Limited, Hetero Labs Limited, Hazelo Lab Private Limited, Piramal Pharma Limited, Sanvira Biosciences Private Limited, Suven Pharmaceuticals Limited, Tagros Chemicals India Private Limited, Vamsi Labs Limited and Viyash Life Sciences Private Limited. The company has eight manufacturing units situated in Hyderabad, Telangana. The company's sales offices are situated in Vadodara, Gujarat, Ankleshwar, Gujarat, Mumbai, Maharashtra and Vishakhapatnam, Andhra Pradesh and sales team members are in Jhagadia, Gujarat, Chennai, Tamil Nadu, New Delhi, Bengaluru, Karnataka and Vijayawada, Andhra Pradesh with pan-India reach. As of September 30, 2024, the company had 460 full-time employees and 731 contract labourers. Competitive Strength Specialised engineering equipment manufacturers for the pharmaceutical and chemical sectors. Customized and innovative range of products throughout the entire pharmaceutical and chemical manufacturing value chain. Strategically located manufacturing facilities with advanced technological capabilities. Long term relationships with marquee clientele across sectors. Consistent track record of profitable growth.

The Company proposes to utilize the Net Proceeds towards funding the following objects: Funding of capital expenditure requirements of the Company towards the purchase of machinery and equipment; Repayment or prepayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company and investment in the wholly owned Material Subsidiary, S2 Engineering Industry Private Limited, for repayment or prepayment, in full or in part, of all or a portion of certain outstanding borrowings availed by S2 Engineering Industry Private Limited, from banks and financial institutions; Investment in the wholly owned Material Subsidiary, S2 Engineering Industry Private Limited, for funding its capital expenditure requirements towards purchase of machinery and equipment; Funding inorganic growth through strategic investments and/or acquisitions and General corporate purposes

All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on Information published on this application. No financial information whatsoever published anywhere, within this application, should be considered as advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever Please read all Tearms and conditions , and agree to use the App